Barely Significant
← all excerpts

Efficacy and safety of <sup>177</sup>Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.

Eur J Nucl Med Mol Imaging · 2022 · PMC9308585 · PMID 35389069

Europe PMCDOI
1
hedged sentence
0.3000
closest p · 6.0× alpha
0.3000
boldest claim

The sentences

did not reach statistical significancep = 0.30not close (p > 0.1)
In the final analysis, with a median follow-up of 6.3 years, treatment with 177 Lu-DOTATATE led to a clinically relevant improvement in median OS of 11.7 months compared with high-dose octreotide LAR, but the difference did not reach statistical significance (HR: 0.84, 95% CI: 0.60–1.17; p = 0.30) [ 19 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.